This newsletter presents you the following key sessions:
1. PODCAST with dr. Leisha Emens about the influence of the tumour microenvironment on the clinical
outcomes of triple-negative breast cancer patients who are treated with atezolizumab plus nab-paclitaxel
2. Marizomib fails to demonstrate clinical benefit in patients with newly diagnosed glioblastoma
3. Meaningful objective response rate with trastuzumab deruxtecan in HER2-associated advanced colorectal
cancer: Updated results from the phase II DESTINY-CRC01 study
4. Durable responses with amivantamab and lazertinib in chemotherapy-naïve patients with EGFR-mutant
NSCLC who relapsed on osimertinib
5. Significantly prolonged invasive disease-free survival with adjuvant olaparib in HER-2 negative high-risk
early breast cancer with BRCA1/2 mutations